OKYO Abstract Selected for Presentation at Premier Global Ophthalmology Congress

Summary by AI BETAClose X

OKYO Pharma Limited announced that its abstract detailing positive Phase 2a clinical trial results for urcosimod in treating neuropathic corneal pain (NCP) has been accepted for presentation at the ARVO 2026 Annual Meeting. The study demonstrated clinically meaningful pain reduction and quality-of-life improvements, with potential for corneal nerve structure restoration. Urcosimod, which holds FDA Fast Track designation for NCP, showed significant pain reduction in 18 NCP patients and is advancing to a planned larger multicenter Phase 2b/3 trial involving approximately 150 patients, expected to initiate in the coming months.

Disclaimer*

UK 100

Latest directors dealings